Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$2.05
-$0.08(-3.76%)
At close: 4:00 PM EDT
$2.05
-$0.08(-3.76%)
Day’s Range― - ―
52-Week Range$0.91 - $4.20
Previous CloseN/A
Volume163.47K
Average Volume (3M)123.78K
Market Cap
$500.38M
Enterprise Value$71.29
Total Cash (Recent Filing)$11.31M
Total Debt (Recent Filing)$425.00K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding173,141,830
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside339.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Oral Peptide Delivery PlatformEntera’s proprietary oral delivery technology is a durable structural advantage: if reproducible across peptides it converts injectable biologics into tablets, improving patient convenience and widening addressable markets. This platform can underpin multiple programs and long-term licensing or partnership value.
Regulatory Clarity On EB613 Phase 3FDA alignment on a single registrational Phase 3 provides clear clinical and regulatory endpoints, reducing development ambiguity and shortening decision-making timelines. This materially lowers execution risk for EB613’s pathway to approval versus an open-ended or multi-protocol approach.
Substantial Strategic Financing And GovernanceThe $275M financing materially extends runway into 2030 and funds Phase 3 and IND milestones. Strategic lead investor BVF adds governance oversight via board representation, improving funding visibility and aligning experienced institutional support with long-term program execution.
Bears Say
Zero Revenue And Persistent Cash BurnThe company remains pre-revenue with substantial negative operating and free cash flow, requiring ongoing external financing. Persistent cash burn limits financial flexibility, increases dilution risk over time, and makes the business dependent on successful clinical readouts or continued capital markets access to sustain operations.
Elevated Dilution And Capital Structure ChangesThe large increase in share authorization and expanded equity plans, plus issuance of pre-funded warrants in recent financings, signal structural dilution risk. Repeated equity raises and incentive grants can meaningfully dilute existing holders and alter long-term ownership and per-share economic value.
Long Timeline And Execution Risk To CommercializationA multi-year path to topline (mid‑2028) means prolonged pre-commercial status and exposure to clinical, regulatory, and operational setbacks. Extended timelines increase cumulative cash needs, magnify the consequences of any delays or negative outcomes, and defer potential revenue realization for investors.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $4.20 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $500.38M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 81 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 173,141,830 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went up 5.923%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (339.02% Upside)
$9.00 (339.02% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 50.1%
Last 30 Days ▲ 50.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.95%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(339.02% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
0.01% Mutual Funds
5.41% Other Institutional Investors
93.23% Public Companies and
Individual Investors